Eli Lilly: unveils 2024 forecasts and ambitions for 2025

(CercleFinance.com) - Eli Lilly forecasts global sales of around $45bn in 2024, up 32% on the previous year.


For Q4 2024, Lilly forecasts global sales of around $13.5bn, up 45% y-o-y.

This includes around $3.5bn for Mounjaro and $1.9bn for Zepbound.

In addition to the growth of Mounjaro and Zepbound, Lilly reports 'strong performance' from its oncology, immunology and neuroscience drugs in Q4 2024.

For 2025, the laboratory anticipates sales of between $58bn and $61bn, thanks to new drugs such as Jaypirca, Ebglyss, Omvoh and Kisunla, approvals for new indications for existing drugs, the launch of Mounjaro in other global markets, as well as potential new drug launches, such as imlunestrant for metastatic breast cancer.

The company currently expects to publish its full financial results for Q4 2024, as well as its financial forecasts for 2025, on 6 February 2025.


Copyright (c) 2025 CercleFinance.com. All rights reserved.